Cargando…

Impact of Stress Hyperglycemia on No-Reflow Phenomenon in Patients with ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

BACKGROUND: Stress hyperglycemia is a common finding during acute myocardial infarction and associated with poor prognosis. To reduce the occurrence of no-reflow, prognostic factors must be identified before primary percutaneous coronary intervention (PPCI). Our objective was to investigate the impa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khalfallah, Mohamed, Maria, Dina A., Allaithy, Amany
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ubiquity Press 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8973831/ https://www.ncbi.nlm.nih.gov/pubmed/35586740 http://dx.doi.org/10.5334/gh.1111

Ejemplares similares

Impact of the Total Ischemia Time on No-Reflow Phenomenon in Patients with ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
por: Khalfallah, Mohamed, et al.
Publicado: (2022)

Incidence, Predictors and Outcomes of Contrast Induced Nephropathy in Patients with ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
por: Khalfallah, Mohamed, et al.
Publicado: (2021)

No reflow phenomenon in percutaneous coronary interventions in ST-segment elevation myocardial infarction
por: Gupta, Sanjiv, et al.
Publicado: (2016)

The Elevated Soluble ST2 Predicts No-Reflow Phenomenon in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
por: Somuncu, Mustafa Umut, et al.
Publicado: (2019)

Incidence, predictors and outcomes of stress hyperglycemia in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention
por: Khalfallah, Mohamed, et al.
Publicado: (2019)

Prediction of no-reflow phenomenon in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction
por: Yang, Li, et al.
Publicado: (2020)

RDW as A Predictor for No-Reflow Phenomenon in DM Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
por: Sun, Ying, et al.
Publicado: (2023)

The predictors of no reflow phenomenon after percutaneous coronary intervention in patients with ST elevation myocardial infarction: A meta-analysis
por: Fajar, Jonny Karunia, et al.
Publicado: (2018)

Serum cystatin C levels relate to no-reflow phenomenon in percutaneous coronary interventions in ST-segment elevation myocardial infarction
por: Cheng, Chao, et al.
Publicado: (2019)

Platelet/lymphocyte ratio for prediction of no-reflow phenomenon in ST-elevation myocardial infarction managed with primary percutaneous coronary intervention
por: Badran, Hala Mahfouz, et al.
Publicado: (2020)

Effect of chronic pretreatment with beta-blockers on no-reflow phenomenon in diabetic patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention
por: Al-Jabari, Ali Mohammed Kareem, et al.
Publicado: (2017)

Novel predictors and adverse long-term outcomes of No-reflow phenomenon in patients with acute ST elevation myocardial infarction undergoing primary percutaneous coronary intervention
por: Refaat, Hesham, et al.
Publicado: (2021)

MELD-XI score predict no-reflow phenomenon and short-term mortality in patient with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
por: Zhang, Xin-Tao, et al.
Publicado: (2022)

Intracoronary Nicorandil and the Prevention of the No-Reflow Phenomenon During Primary Percutaneous Coronary Intervention in Patients with Acute ST-Segment Elevation Myocardial Infarction
por: Qi, Qi, et al.
Publicado: (2018)

Utility of Hematological Parameters in Predicting No-Reflow Phenomenon After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction
por: Wang, Zuoyan, et al.
Publicado: (2018)

Predictors and outcome of no-reflow post primary percutaneous coronary intervention for ST elevation myocardial infarction
por: Mazhar, Jawad, et al.
Publicado: (2015)

The role of SCUBE1 in the pathogenesis of no-reflow phenomenon presenting with ST segment elevation myocardial infarction
por: Bolayır, Hasan Ata, et al.
Publicado: (2017)

Effect of intracoronary agents on the no-reflow phenomenon during primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: a network meta-analysis
por: Niu, Xiaowei, et al.
Publicado: (2018)

No-reflow phenomenon and comparison to the normal-flow population postprimary percutaneous coronary intervention for ST elevation myocardial infarction: case–control study (NORM PPCI)
por: Rossington, Jennifer Ann, et al.
Publicado: (2020)

CHA2DS2 VASc score and brachial artery flow-mediated dilation as predictors for no-reflow phenomenon in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
por: Rashed, Mohamed Ismail, et al.
Publicado: (2022)

Canada acute coronary syndrome risk score predicts no-/slow-reflow in ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention
por: Xie, Enmin, et al.
Publicado: (2023)

LncRNA MALAT1 functions as a biomarker of no-reflow phenomenon in ST-segment elevation myocardial infarction patients receiving primary percutaneous coronary intervention
por: Yang, Xiheng, et al.
Publicado: (2022)

Very Early Versus Early Percutaneous Coronary Intervention in Patients with Decreased e-GFR after Successful Fibrinolytic Therapy
por: Khalfallah, Mohamed, et al.
Publicado: (2020)

Comparison of no-reflow phenomenon after percutaneous coronary intervention for acute myocardial infarction between smokers and nonsmokers
por: Shemirani, Hassan, et al.
Publicado: (2014)

Relation of hemoglobin level to no-reflow in patients with ST-segment elevation myocardial infarction undergoing primary coronary intervention
por: Yaylak, Barış, et al.
Publicado: (2018)

CHA(2)DS(2)-VASc score predicts the slow flow/no-reflow phenomenon in ST-segment elevation myocardial infarction patients with multivessel disease undergoing primary percutaneous coronary intervention
por: Huang, Xin, et al.
Publicado: (2021)

Growth Differentiation Factor 15 as a Predictor of the No-Reflow Phenomenon in Patients with ST-Segment Elevation Myocardial Infarction
por: Kożuch, Marcin, et al.
Publicado: (2022)

Correlation between endothelial dysfunction and occurrence of no-reflow in patients undergoing post-thrombolysis early invasive percutaneous intervention for ST-elevation myocardial infarction
por: Elbendary, Mohamed Abdel Wahab, et al.
Publicado: (2022)

New CHA(2)DS(2)-VASc-HSF score predicts the no-reflow phenomenon after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction
por: Zhang, Qin-Yao, et al.
Publicado: (2020)

Correlates of the “No-Reflow” or “Slow-Flow” Phenomenon in Patients Undergoing Primary Percutaneous Coronary Intervention
por: Alidoosti, Mohammad, et al.
Publicado: (2018)

Effect of preoperative loading dose ticagrelor and clopidogrel on no-reflow phenomenon during intervention in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis
por: Dai, Weiran, et al.
Publicado: (2018)

The predictive value of R-wave peak time on no-reflow in patients with ST-elevation myocardial infarction treated with a primary percutaneous coronary intervention
por: Bendary, Ahmed, et al.
Publicado: (2018)

Effects of no-reflow phenomenon on ventricular systolic synchrony in patients with acute anterior myocardial infarction after percutaneous coronary intervention
por: Wang, Le, et al.
Publicado: (2016)

Intracoronary pressure gradient measurement in acute myocardial infarction patients with the no-reflow phenomenon during primary percutaneous coronary intervention
por: Gao, Ming-Dong, et al.
Publicado: (2020)

Association between the No-Reflow Phenomenon and Soluble CD40 Ligand Level in Patients with Acute ST-Segment Elevation Myocardial Infarction
por: Tascanov, Mustafa Begenc, et al.
Publicado: (2019)

Acute Profound Thrombocytopenia after Using Abciximab for No-Reflow during Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction
por: Park, Soonyoung, et al.
Publicado: (2013)

Machine learning to predict no reflow and in-hospital mortality in patients with ST-segment elevation myocardial infarction that underwent primary percutaneous coronary intervention
por: Deng, Lianxiang, et al.
Publicado: (2022)

A nomogram for predicting the risk of no-reflow after primary percutaneous coronary intervention in elderly patients with ST-segment elevation myocardial infarction
por: Yang, Li, et al.
Publicado: (2021)

Risk Factors for No-Reflow in Patients with ST-Elevation Myocardial Infarction Who Underwent Percutaneous Coronary Intervention: A Case-Control Study
por: Yu, Ying, et al.
Publicado: (2022)

Using an Artificial Neural Network to Predict Coronary Microvascular Obstruction (No-Reflow Phenomenon) during Percutaneous Coronary Interventions in Patients with Myocardial Infarction
por: Frolov, A.A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_g9v76aheibe6t1qj19c764vpkj